WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) reported a return to profitability in the second quarter, driven by the termination of a regional licensing deal and renewed strategic ...

Detailed price information for Arbutus Biopharma Corp (ABUS-Q) from The Globe and Mail including charting and trades.

Arbutus (ABUS) delivered earnings and revenue surprises of +150.00% and +496.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Arbutus Biopharma Corp. ABUS) on Wednesday reported second-quarter net income of $2.5 million, after reporting a loss in the ...

On July 24, 2025, the PTO Acting Director Coke Morgan Stewart discretionarily denied Amgen’s IPR2025-00601 and IPR2025-00602 challenging ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Surveillance of hepatocellular carcinoma (HCC), via 6-monthly ultrasonography with alpha-fetoprotein testing, is currently ...

Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignatio ...

Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 1st. Analysts expect Arbutus Biopharma to ...

Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Wednesday ...